Extended Treatment and Follow-up of Subjects Treated With Belumosudil in Study KD025-208 or Study KD025-213

Inclusion Criteria:

Subjects must have been treated with belumosudil for at least 1 of the following:

   - Actively receiving belumosudil on Study KD025-208 or Study KD025-213

   - Is in Long-term Follow-up (LTFU) on Study KD025-208 or Study KD025-213. Long-term
   Follow-up will be defined as the period after ending treatment with belumosudil and
   until a FFS event occurs.

   - Adult enrolled in the Companion Study under KD025-213 Amendment 2 (01 June 2020) and
   has received at least 6 months of treatment of belumosudil or is in LTFU

Exclusion Criteria:

   - Female subject who is pregnant or breastfeeding

   - Subject considered unlikely to adhere to treatment and/or follow protocol in the
   opinion of the Investigator